Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuki Yamashita has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Perihepatic dedifferentiated liposarcoma mimicking IgG4-related disease

    by Soushi Shibusawa, Yuki Yamashita, Tomoyuki Tanaka, Takefumi Kimura, Shusei Sano, Hisashi Tamada, Yusuke Oka, Yoshiki Ozawa, Hiromitsu Mori, Shuichi Wada

    Dedifferentiated liposarcoma (DDLPS) may originate in perihepatic adipose tissue, but can radiologically present as a hepatic mass. Moreover, dense Immunoglobulin G4 (IgG4)-positive plasma cell infiltration may mimic IgG4-related disease (IgG4-RD) and delay curative-intent resection. We herein describe a unique case that exemplifies this diagnostic pitfall. A 67-year-old woman was incidentally found to harbor a hepatic mass in segment 6 along with small mesenteric nodules. Cross-sectional imaging showed heterogeneous non-fat containing lesions, while needle biopsy revealed abundant IgG4-positive plasma cells. Prednisolone treatment was commenced for presumed IgG4-related inflammatory pseudotumor. Although the lesions initially shrank slightly, they both enlarged during steroid tapering. Segment 6 hepatectomy with limited bowel resection was subsequently performed. Pathohistological examination revealed atypical stromal cells arising in perihepatic adipose tissue, and Mouse double minute protein 2 (MDM2) amplification confirmed liposarcoma infiltration into the liver and mesentery. Following the discontinuation of steroids, the patient has remained recurrence-free for fourteen months after surgery. DDLPS can masquerade as IgG4-RD and even show temporary steroid responsiveness. When clinical or imaging treatment findings are atypical, comprehensive tissue evaluation with molecular analysis is essential to prevent diagnostic delay.

  • Extra-intestinal Edwardsiella tarda infection presenting as sequential cholecystitis and cholangitis: a case report

    by Keigo Yoshimura, Yuki Yamashita, Takefumi Kimura, Yusuke Oka, Yoshiki Ozawa, Shohei Kondo, Koujiro Tokutake, Tetsuya Ito, Hiromitsu Mori, Shuichi Wada

    Background Edwardsiella tarda (E. tarda) is a rare human pathogen. Extra-intestinal infections of E. tarda are particularly uncommon, with only one case of recurrent cholangitis caused by E. tarda reported to date. Case presentation A 77-year-old man suffered acute calculous cholecystitis 5 days after eating eel and raw fish. Culture results from bile obtained via percutaneous gallbladder drainage revealed E. tarda infection, and an 8-day course of intravenous cefmetazole led to clinical resolution. However, the patient returned with fever and laboratory signs of obstructive cholangitis 5 weeks later. Contrast-enhanced computed tomography showed a migrated gallstone in the distal common bile duct. Endoscopic retrograde cholangiopancreatography drained the purulent bile, and cultures from the bile and blood were again positive for E. tarda. A 10-day course of cefmetazole, along with biliary stent placement resulted in complete recovery. Conclusion E. tarda can cause relapsing biliary tract infections despite appropriate initial treatment. Clinicians should consider this rare pathogen in cases of recurrent cholangitis, especially for patients with recent consumption of raw or undercooked aquatic animals. A detailed dietary history and targeted microbiological testing are essential for accurate diagnosis and management.

  • Open Access

    AI‐Based Platelet‐Independent Noninvasive Test for Liver Fibrosis in MASLD Patients

    by Shun‐Ichi Wakabayashi, Takefumi Kimura, Nobuharu Tamaki, Takanobu Iwadare, Taiki Okumura, Hiroyuki Kobayashi, Yuki Yamashita, Naoki Tanaka, Masayuki Kurosaki, Takeji Umemura

    Background and Aim: Noninvasive tests (NITs), such as platelet‐based indices and ultrasound/MRI elastography, are widely used to assess liver fibrosis in metabolic dysfunction‐associated steatotic liver disease (MASLD). However, platelet counts are not routinely included in Japanese health check‐ups, limiting their utility in large‐scale screenings. Additionally, elastography, while effective, is costly and less accessible in routine practice. Most existing AI‐based models incorporate these markers, restricting their applicability. This study aimed to develop a simple yet accurate AI model for liver fibrosis staging using only routine demographic and biochemical markers.Methods: This retrospective study analyzed biopsy‐proven data from 463 Japanese MASLD patients. Patients were randomly assigned to training (N = 370, 80%) and test (N = 93, 20%) cohorts. The AI model incorporated age, sex, BMI, diabetes, hypertension, hyperlipidemia, and routine blood markers (AST, ALT, γ‐GTP, HbA1c, glucose, triglycerides, cholesterol).Results: The Support Vector Machine model demonstrated high diagnostic performance, with an area under the curve (AUC) of 0.886 for detecting significant fibrosis (≥ F2). The AUCs for advanced fibrosis (≥ F3) and cirrhosis (F4) were 0.882 and 0.916, respectively. Compared to FIB‐4, APRI, and FAST score (0.80–0.96), SVM achieved comparable accuracy while eliminating the need for platelet count or elastography.Conclusion: This AI model accurately assesses liver fibrosis in MASLD patients without requiring platelet count or elastography. Its simplicity, cost‐effectiveness, and strong diagnostic performance make it well‐suited for large‐scale health screenings and routine clinical use.


  • Hormone replacement therapy for steatotic liver management after surgical menopause

    by Yoshiaki Kobayashi, Yuki Yamashita, Takefumi Kimura, Takanobu Iwadare, Taiki Okumura, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Ayumi Sugiura, Satoru Joshita, Takeji Umemura

    Although steatotic liver onset after natural menopause has been reported, evidence on the clinical course and treatment options for steatotic liver after surgical menopause is scarce. A 34-year-old woman with a history of severe obesity presented to our department with liver dysfunction following total hysterectomy and bilateral oophorectomy. Her serum estradiol level was notably low at 22 pg/mL, and a liver biopsy revealed significant fatty degeneration, lobular inflammation, hepatocyte ballooning, and stage F1 fibrosis. These findings supported a diagnosis of steatotic liver disease following surgical menopause. Subsequent initiation of hormone replacement therapy (HRT) with estrogen led to rapid improvements in liver function and steatotic liver symptoms. Steatotic liver disease should be considered in cases of liver impairment in postoperative menopausal patients, for which HRT represents a promising treatment option.

  • Open Access

    Serum Autotaxin Levels Predict Liver-Related Events in Patients With Primary Biliary Cholangitis: A Long-Term Multicenter Observational Study

    by Takanobu Iwadare, Takefumi Kimura, Yuki Yamashita, Taiki Okumura, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Ayumi Sugiura, Tomoo Yamazaki, Satoshi Shimamoto, Koji Igarashi, et al.

    INTRODUCTION: A straightforward, reliable, and noninvasive method for predicting the development of liver-related events (LRE) in primary biliary cholangitis (PBC) has not been attained thus far. This study investigated whether serum autotaxin (ATX) could predict LRE in patients with PBC. METHODS: This retrospective multicenter investigation included 190 biopsy-proven untreated patients with PBC. All subjects were followed for at least 1 year, during which time the prevalence of LRE, including newly developing hepatocellular carcinoma, esophagogastric varices, ascites, and hepatic encephalopathy, was investigated in relation with ATX levels at the time of liver biopsy. RESULTS: During the median follow-up period of 9.7 years, LRE were observed in 22 patients (11.6%). The area under the receiver operating characteristic curve and cutoff value of serum ATX for predicting LRE were 0.80 and 1.086 mg/L, respectively. Patients with serum ATX ≥1.086 had a significantly higher cumulative incidence of LRE compared with patients with ATX < 1.086 (33.3% vs 3.6%, P < 0.00001). Notably, the predictive capability of ATX for LRE in patients with PBC surpassed that of FIB-4, ALBI, APRI, and Mac-2-binding protein glycan isomer. A multivariate Cox proportional hazards model revealed ATX as an independent associated factor for LRE (hazard ratio 6.24, 95% confidence interval 1.87–20.80, P = 0.003) along with Nakanuma stage (hazard ratio 2.75, 95% confidence interval 1.52–4.99, P < 0.001). These results were closely replicated in a serologically diagnosed PBC validation cohort (n = 32). DISCUSSION: Serum ATX levels may serve as a predictive marker for LRE in patients with PBC.


  • Open Access

    Prognostic Significance of C-Reactive Protein in Lenvatinib-Treated Unresectable Hepatocellular Carcinoma: A Multi-Institutional Study

    by Taiki Okumura, Takefumi Kimura, Takanobu Iwadare, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Satoru Joshita, Naoyuki Fujimori, Hideo Kunimoto, et al.

    Background: Serum C-reactive protein (CRP) is an established biomarker for acute inflammation and has been identified as a prognostic indicator for hepatocellular carcinoma (HCC). However, the significance of the serum CRP level, specifically in HCC patients treated with lenvatinib, remains unclear. Methods: We retrospectively analyzed 125 HCC patients who received lenvatinib treatment at six centers. Clinical characteristics were assessed to identify clinical associations between serum CRP and HCC prognosis. Results: The median overall serum CRP level was 0.29 mg/dL. The cohort was divided into two groups: the low-CRP group with a serum CRP < 0.5 mg/dL and the high-CRP group with a serum CRP ≥ 0.5 mg/dL. The low-CRP group exhibited significantly longer overall survival (OS) than the high-CRP group (22.9 vs. 7.8 months, p < 0.001). No significant difference was observed for progression-free survival (PFS) between the high- and low-CRP groups (9.8 vs. 8.4 months, p = 0.411), while time-to-treatment failure (TTF) was significantly longer in the low-CRP group (8.5 vs. 4.4 months, p = 0.007). The discontinuation rate due to poor performance status was significantly higher in the high-CRP group (p < 0.001). Conclusion: A baseline serum CRP level exceeding 0.5 mg/dL was identified as an unfavorable prognostic factor in HCC patients receiving lenvatinib treatment.


  • Open Access

    Symptom‐based portopulmonary hypertension screening questionnaire in Japanese patients with chronic liver disease

    by Shun‐Ichi Wakabayashi, Satoru Joshita, Kazuhiro Kimura, Hirohiko Motoki, Taiki Okumura, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Tomoo Yamazaki, Takefumi Kimura, et al.

    Background and AimAs the exact prevalence of portopulmonary hypertension (PoPH) and the etiology of chronic liver disease (CLD) remain unknown, the present study aimed to clarify these points in Japanese patients with CLD using symptom-based questionnaire screening. MethodsPatients with CLD were asked to complete an eight-item written questionnaire on pulmonary hypertension (PH) symptoms. If at least one item response was "yes," the patient was offered ultrasonic echocardiography (UCG). Patients identified as having an intermediate or high risk of PH by UCG were referred to a cardiologist for further evaluation, whereby a definitive diagnosis of PoPH was made using right heart catheterization (RHC) findings. ResultsA total of 1111 patients with CLD completed the survey. Of the 566 symptomatic patients with at least one question answered as "yes," approximately half agreed to undergo UCG (n = 267). Compared with asymptomatic patients, symptomatic patients were significantly older, predominantly female, and more frequently exhibited cirrhosis. Based on UCG findings, 228, 12, and 8 patients had a low, intermediate, or high risk for PH, respectively. Intermediate-/high-risk patients showed significantly more advanced disease progression status than low-risk patients. The frequencies of answer to the eight questions were comparable. Ultimately, three patients were diagnosed as having PoPH (1.1% of UCG cases), one with underlying hepatitis C virus (HCV) infection and two with primary biliary cholangitis (PBC). ConclusionThis symptom-based PoPH screening study clarified the prevalence of PoPH in CLD patients according to a PH symptom questionnaire, UCG, and RHC. Patients with HCV and PBC may have a higher risk of PoPH.


  • HLA-G susceptibility to hepatitis B infection and related hepatocellular carcinoma in the Japanese population

    by Taiki Okumura, Satoru Joshita, Tomoo Yamazaki, Takanobu Iwadare, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Takefumi Kimura, Masao Ota, et al.


  • Open Access

    Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis

    by Yuki Yamashita, Takeji Umemura, Takefumi Kimura, Satoru Joshita, Junko Hirohara, Toshiaki Nakano, Atsumasa Komori, Atsushi Tanaka


  • Open Access

    Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD

    by Takanobu Iwadare, Takefumi Kimura, Hideo Kunimoto, Naoki Tanaka, Shun-Ichi Wakabayashi, Tomoo Yamazaki, Taiki Okumura, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, et al.

    Aim: Pemafibrate (PEM) is a novel selective peroxisome proliferator-activated receptor alpha modulator that is effective for hypertriglyceridemia accompanying non-alcoholic fatty liver disease (HTG-NAFLD). This study aimed to identify the predictors of PEM efficacy for HTG-NAFLD in clinical practice. Methods: We retrospectively enrolled 88 HTG-NAFLD patients treated with PEM for 6 months for the analysis of routine blood and body composition testing. A PEM response was defined as a decrease in serum alanine aminotransferase (ALT) of >30% compared with pre-treatment level. The clinical features related to PEM responsiveness were statistically tested between responders and non-responders. Results: All 88 patients completed the 6 month drug regimen without any adverse effects. PEM treatment significantly decreased liver enzymes, triglycerides, and total cholesterol levels, without any detectable impact on body weight or body composition. Comparisons of baseline clinical features revealed female and greater aspartate aminotransferase (AST), ALT, and fat mass % levels to be significantly associated with a PEM response. The optimal cut-off values to predict responders as determined by receiver operating characteristic analysis were AST 45 U/L, ALT 60 U/L, and fat mass 37%. Conclusions: Female HTG-NAFLD patients with higher transaminase and fat mass % levels may be preferentially indicated for PEM treatment. Additional large-scale prospective studies are warranted to verify our results.